Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients

被引：0

作者：

Nishio, Minako ^{[1
]}

Kojitani, Yoshiki ^{[1
]}

Kitashiro, Saya ^{[1
]}

Ishiduka, Yasunobu ^{[1
]}

Otsuka, Tomoyuki ^{[1
]}

Nishida, Naohiro ^{[1
]}

Fujisawa, Fumie ^{[1
]}

Sugimoto, Naotoshi ^{[1
]}

Yagi, Toshinari ^{[1
]}

Souma, Ai ^{[2
]}

Kanaoka, Haruka ^{[2
]}

Oyamayama, Yuri ^{[2
]}

Taniguchi, Azusa ^{[2
]}

Nakajima, Satomi ^{[2
]}

Seto, Yukiko ^{[2
]}

Kusama, Hiroki ^{[2
]}

Watanabe, Noriyuki ^{[2
]}

Matsui, Saki ^{[2
]}

Nakayama, Takahiro ^{[2
]}

Kudou, Toshihiro ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Med Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Breast Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.3098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P67-5

引用

页码：S1465 / S1465

页数：1

共 50 条

[31] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
Nina D’Abreo
Sylvia Adams
Nature Reviews Clinical Oncology, 2019, 16 : 399 - 400
[32] Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Simona Camorani
Margherita Passariello
Lisa Agnello
Silvia Esposito
Francesca Collina
Monica Cantile
Maurizio Di Bonito
Ilya V. Ulasov
Monica Fedele
Antonella Zannetti
Claudia De Lorenzo
Laura Cerchia
Journal of Experimental & Clinical Cancer Research, 39
[33] Triple-negative breast cancer - a Hispanic experience
Mortera Casillas, J.
Cabrera Galeana, P.
Tellez Trevilla, G.
Gomez Garcia, E.
Serrano Ortiz, R.
Barrera Franco, J. L.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S312 - S313
[34] LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
Zhou, Jialin
Feng, Chun
Huang, Kai
FRONTIERS IN ONCOLOGY, 2022, 12
[35] A meta-analysis of the efficacy of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer
Li, Y.
Xing, L.
Yin, X.
Li, H.
Ren, G.
ANNALS OF ONCOLOGY, 2021, 32 : S50 - S51
[36] Benefit with re-challenge of immune checkpoint inhibitors in patient with metastatic triple-negative breast cancer: a case report
Zhou, Jinmei
Wang, Tao
Bian, Li
Li, Jianbin
Jiang, Zefei
TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
[37] Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis
Mittal, Niti
Singh, Surjit
Mittal, Rakesh
Kaushal, Jyoti
Kaushal, Vivek
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1754 - +
[38] Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response
Wang, Ce
Feng, Guoshuang
Zhu, Jingjing
Wei, Kecheng
Huang, Chen
Wu, Zhenyu
Yu, Yongfu
Qin, Guoyou
FUTURE ONCOLOGY, 2022, 18 (09) : 1055 - 1066
[39] Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors
Chen, Xin-Yu
Li, Bin
Wang, Ye
Jin, Juan
Yang, Yu
Huang, Lei-Huan
Yang, Meng-Di
Zhang, Jian
Wang, Bi-Yun
Shao, Zhi-Ming
Ni, Ting
Huang, Sheng-Lin
Hu, Xi-Chun
Tao, Zhong-Hua
CANCER COMMUNICATIONS, 2023, 43 (09) : 1003 - 1026
[40] ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
Chen, Margaret
Li, Bin
Wang, Ye
Hu, Xichun
Tao, Zhonghua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →